<DOC>
	<DOC>NCT00742508</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of SK&amp;F-105517-D in japanese patients with chronic heart failure.</brief_summary>
	<brief_title>A Phase I/II Clinical Study of SK&amp;F-105517-D in Japanese Patients With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Inclusion criteria: Patients with symptomatically stable chronic heart failure (CHF) based on ischemic heart disease or dilated cardiomyopathy Patients who are maintained on basic heart failure therapy with angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blocker (ARB) and their dosage/administration is not changed within 2 weeks Patients diagnosed with New York Heart Association (NYHA) class I to III Patients with a left ventricular ejection fraction (LVEF) between 25% and 45% Patients contraindicated for ßblockers Patients with occurrence of acute myocardial infarction within 2 weeks Patients with unstable angina, coronary spastic angina, or angina at rest Patients who have collected blood &gt;400 mL within 4 months prior to screening or &gt;200 mL within 1 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>carvedilol phosphate</keyword>
	<keyword>ß-blocker</keyword>
	<keyword>SK&amp;F-105517-D</keyword>
	<keyword>Chronic heart failure(CHF)</keyword>
</DOC>